Coherus BioSciences (CHRS) Misses Q4 EPS by 19c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Coherus BioSciences Reports Fourth Quarter and Full Year 2019 Financial Results
February 27, 2020 4:01 PM ESTFull Year UDENYCA® Sales of $356.1 Million
Full Year Cash Flow from Operating Activities of $28.4 million
REDWOOD CITY, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus or the Company, Nasdaq: CHRS), today reviewed corporate events and reported financial results for the quarter and full year ended December 31, 2019.Â
Fourth Quarter 2019 and Recent Corporate Highlights
Coherus commercial capabilities advanced its core mission to expand choice, improve patient access and lower healthcare costs in the United States:
UDENYCA® (pegfilgrastim-cbqv) launch continues to deliver... More